2015 Fiscal Year Final Research Report
Clinical application of activated NK cell therapy
| Project/Area Number |
25461443
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Tokyo Women's Medical University |
|---|
Principal Investigator |
Tanaka Junji 東京女子医科大学, 医学部, 教授 (50250452)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | NK細胞 / 細胞療法 / 悪性リンパ腫 |
|---|
| Outline of Final Research Achievements |
We could establish the GMP-grade clinical NK cell expansion system under the condition with OKT3, tacrolimus, dalteparin and cytokines such as IL-2 and IL-15 using peripheral blood mononuclear cells (PBMC) from patients with hematological malignancies such as malignant lymphoma. Expanded NK cell had strong cytolytic activity against K562 human leukemic cell line without pre-sensitization. Using this system, we could planed autologous expanded NK cell therapy clinical trial with rituximab (Phase I/II) against relapse/refractory B cell malignant lymphoma.
|
| Free Research Field |
血液内科学
|
